EVA MARÍA
CIRUELOS GIL
Profesora asociada de Ciencias de la Salud
University of Padua
Padua, ItaliaPublicaciones en colaboración con investigadores/as de University of Padua (11)
2021
-
Alpelisib plus fulvestrant for PIK3CA-mutated, hormone receptor-positive, human epidermal growth factor receptor-2–negative advanced breast cancer: final overall survival results from SOLAR-1
Annals of Oncology, Vol. 32, Núm. 2, pp. 208-217
-
Patient-Reported Outcomes in Patients With PIK3CA-Mutated Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer From SOLAR-1
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 39, Núm. 18, pp. 2005-2015
2020
-
A multivariable prognostic score to guide systemic therapy in early-stage HER2-positive breast cancer: a retrospective study with an external evaluation
The Lancet Oncology, Vol. 21, Núm. 11, pp. 1455-1464
-
Everolimus plus exemestane in hormone-receptor-positive, HER2-negative locally advanced or metastatic breast cancer: incidence and time course of adverse events in the phase IIIb BALLET population
Clinical and Translational Oncology, Vol. 22, Núm. 10, pp. 1857-1866
-
Impact of BMI on the outcome of metastatic breast cancer patients treated with everolimus: a retrospective exploratory analysis of the BALLET study
Oncotarget, Vol. 11, Núm. 23, pp. 2172-2181
-
Phenotypic changes of HER2-positive breast cancer during and after dual HER2 blockade
Nature Communications, Vol. 11, Núm. 1
-
Time course and management of key adverse events during the randomized phase III SOLAR-1 study of PI3K inhibitor alpelisib plus fulvestrant in patients with HR-positive advanced breast cancer
Annals of Oncology, Vol. 31, Núm. 8, pp. 1001-1010
2019
-
Alpelisib for PIK3CA-mutated, hormone receptor-positive advanced breast cancer
New England Journal of Medicine, Vol. 380, Núm. 20, pp. 1929-1940
2016
-
A phase III study of alpelisib and fulvestrant in men and postmenopausal women with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–) advanced breast cancer (BC) progressing on or after aromatase inhibitor (AI) therapy (SOLAR-1)
Annals of Oncology, Vol. 27, pp. vi98
-
Safety of everolimus plus exemestane in patients with hormone-receptor-positive, HER2-negative locally advanced or metastatic breast cancer progressing on prior non-steroidal aromatase inhibitors: Primary results of a phase IIIb, open-label, single-arm, expanded-access multicenter trial (BALLET)
Annals of Oncology, Vol. 27, Núm. 9, pp. 1719-1725